Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
Identifieur interne : 000308 ( PubMed/Curation ); précédent : 000307; suivant : 000309Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
Auteurs : Abdulrahman Almasaud [Arabie saoudite] ; Naif Khalaf Alharbi [Arabie saoudite] ; Anwar M. Hashem [Arabie saoudite]Source :
- Methods in molecular biology (Clifton, N.J.) [ 1940-6029 ] ; 2020.
Abstract
Pseudotyped viral particle production has been used extensively and broadly for many viruses to evaluate levels of neutralizing antibodies, viral entry inhibitors and vaccine immunogenicity. This assay is extremely safe and useful alternative to live virus-based assay without the need for high containment facilities. In this chapter, we describe the generation of MERS-CoV pseudotyped viral particles (MERSpp) expressing full-length spike protein using second-generation lentiviral packaging system. This platform is optimized to generate high titer of MERSpp and to test sera from different mammalian species.
DOI: 10.1007/978-1-0716-0211-9_10
PubMed: 31883092
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000308
Links to Exploration step
pubmed:31883092Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.</title><author><name sortKey="Almasaud, Abdulrahman" sort="Almasaud, Abdulrahman" uniqKey="Almasaud A" first="Abdulrahman" last="Almasaud">Abdulrahman Almasaud</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. harbina2@ngha.med.sa.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Hashem, Anwar M" sort="Hashem, Anwar M" uniqKey="Hashem A" first="Anwar M" last="Hashem">Anwar M. Hashem</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31883092</idno><idno type="pmid">31883092</idno><idno type="doi">10.1007/978-1-0716-0211-9_10</idno><idno type="wicri:Area/PubMed/Corpus">000308</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000308</idno><idno type="wicri:Area/PubMed/Curation">000308</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000308</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.</title><author><name sortKey="Almasaud, Abdulrahman" sort="Almasaud, Abdulrahman" uniqKey="Almasaud A" first="Abdulrahman" last="Almasaud">Abdulrahman Almasaud</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. harbina2@ngha.med.sa.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Hashem, Anwar M" sort="Hashem, Anwar M" uniqKey="Hashem A" first="Anwar M" last="Hashem">Anwar M. Hashem</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author></analytic><series><title level="j">Methods in molecular biology (Clifton, N.J.)</title><idno type="eISSN">1940-6029</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pseudotyped viral particle production has been used extensively and broadly for many viruses to evaluate levels of neutralizing antibodies, viral entry inhibitors and vaccine immunogenicity. This assay is extremely safe and useful alternative to live virus-based assay without the need for high containment facilities. In this chapter, we describe the generation of MERS-CoV pseudotyped viral particles (MERSpp) expressing full-length spike protein using second-generation lentiviral packaging system. This platform is optimized to generate high titer of MERSpp and to test sera from different mammalian species.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31883092</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN><JournalIssue CitedMedium="Internet"><Volume>2099</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Methods in molecular biology (Clifton, N.J.)</Title><ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation></Journal><ArticleTitle>Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.</ArticleTitle><Pagination><MedlinePgn>117-126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-0211-9_10</ELocationID><Abstract><AbstractText>Pseudotyped viral particle production has been used extensively and broadly for many viruses to evaluate levels of neutralizing antibodies, viral entry inhibitors and vaccine immunogenicity. This assay is extremely safe and useful alternative to live virus-based assay without the need for high containment facilities. In this chapter, we describe the generation of MERS-CoV pseudotyped viral particles (MERSpp) expressing full-length spike protein using second-generation lentiviral packaging system. This platform is optimized to generate high titer of MERSpp and to test sera from different mammalian species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almasaud</LastName><ForeName>Abdulrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alharbi</LastName><ForeName>Naif Khalaf</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. harbina2@ngha.med.sa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. harbina2@ngha.med.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashem</LastName><ForeName>Anwar M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, Research Center, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Methods Mol Biol</MedlineTA><NlmUniqueID>9214969</NlmUniqueID><ISSNLinking>1064-3745</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS-CoV</Keyword><Keyword MajorTopicYN="Y">Neutralization assay</Keyword><Keyword MajorTopicYN="Y">Pseudotype viral particles</Keyword><Keyword MajorTopicYN="Y">Pseudovirus</Keyword><Keyword MajorTopicYN="Y">Transfection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31883092</ArticleId><ArticleId IdType="doi">10.1007/978-1-0716-0211-9_10</ArticleId><ArticleId IdType="pmc">PMC7123069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Exp Med. 1910 Sep 1;12(5):696-705</Citation><ArticleIdList><ArticleId IdType="pubmed">19867354</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Immunol. 2015 Apr 29;6:161</Citation><ArticleIdList><ArticleId IdType="pubmed">25972865</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Gene Ther. 2005 Aug;5(4):387-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16101513</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Chem. 2015 Jun;61(6):885-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25829407</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8640-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9238030</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MethodsX. 2015 Oct 13;2:379-84</Citation><ArticleIdList><ArticleId IdType="pubmed">26587388</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Genet. 1997 Jan;15(1):57-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8988169</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MethodsX. 2016 Dec 15;4:11-24</Citation><ArticleIdList><ArticleId IdType="pubmed">28070500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2016 Sep;97(9):2265-2279</Citation><ArticleIdList><ArticleId IdType="pubmed">27384448</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Dec;72(12):9873-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9811723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:31883092
|texte= Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31883092" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |